Uterine arteriovenous malformation: A retrospective study from a tertiary center in southern Karnataka

Introduction

Uterine arteriovenous malformation (AVM) is a rare, life-threatening condition. It is characterized by abnormal connections between the arteries and veins of the uterine myometrium. However, the exact prevalence of this condition remains unknown. These can be congenital or acquired. Acquired uterine AVMs are sometimes recognized as having enhanced myometrial vascularity (EVM). It refers to any uterine pathology resulting in increased myometrial vascularity regardless of residual tissue at conception.^1,2 Uterine acquired AVMs are typically noticed in a multipara woman in her thirties.³ The common manifestations are menorrhagia, symptoms of anemia and catastrophic hemorrhage, which can lead to significant morbidity and, rarely, mortality. Ultrasound and CT angiography were the main diagnostic tests used. Treatment is generally multidisciplinary and involves obstetricians, radiologists, transfusion medicine professionals, and interventional radiologists. Medical, interventional (uterine artery embolization) and surgical methods are the different management modalities.

The objective of this study was to systematically study cases of acquired arteriovenous malformation and their impact on health. The article has followed strobe guidelines for the reporting of data.

Materials and methods

First, this was a retrospective study. Ethical committee clearance was also obtained in 23^rd April 2025. (IEC1-166/2025). The search was performed from January 2021 to February 2025 for all patients admitted with an AVM diagnosis. Details of the AVM cases were obtained from the electronic database system or from the medical records section of the Kasturba Medical College, Manipal, Karnataka. Patient enrollment was performed only after confirmation of the diagnosis by uterine power Doppler or after imaging with angiography. Informed written consent was obtained. Data concerning the patient’s age, presenting symptoms, obstetric history, comorbid conditions, detection modality, and treatment provided were obtained. Patients with inconclusive diagnoses were excluded from the study.

Results

During the abovementioned time frame, a total of 19 cases of AV malformation were found, and 15 cases had appropriate doppler or higher imaging diagnosis. Patient characteristics are summarized in Table 1. The age range of the patients was 24–40 years. The presenting symptom was bleeding or spotting per vagina in 93.3% of patients. A total of 86.8% of patients were referred, and a referral was observed 4 days to 10 weeks after the trigger event. A total of 13.2% of patients had severe multiple system involvement. The distribution of gravidae was as follows: primary (33.3%), second (26.6%), third (19.9%), fourth (13.2%), and fifth (6.6%) gravidae. A total of 46.2% had previous cesarean sections and 19% had undergone vaginal delivery. A total of 19.98% of women had a history of previous pregnancy mishaps in the form of first-trimester abortions. A total of 93.34% of women had early pregnancy loss or MTP as an inciting event between 5 and 14 weeks. A total of 79.9% of patients required dilatation and curettage (D&C) or MVA before or after AVM diagnosis. One patient presented with normal delivery. The reported hemoglobin level was between 4.2 and 11 during treatment, and 46.2% of the patients received blood ± blood product transfusions. hCG observed at the time of admission varied between 0.1 and 109 mIU/ml, which became negative during follow-up visits. Two patients delivered after treatment (Uterine Artery Embolization), one of whom had stage 1 gestational trophoblastic neoplasia.

The diagnostic modalities and treatments are summarized in Table 2. All patients underwent transvaginal ultrasound, and confirmation was provided by CT angiography in 59.4%, MRI angiography in 19.9%, digital subtraction angiography (DSA) in 13.3%, and contrast-enhanced computed tomography (CECT) in 6.6%. We observed that posterior uterine wall lesions were more common than anterior uterine wall lesions. The final treatment options included uterine artery embolization/transcatheter embolization (TCE) (66%), surgical hysterectomy (6.6%), and conservative management (26.6%). Failure of conservative management was observed in 2 patients (one after treatment with OC pills and one after treatment with progesterone). Injectable leuprolide (2 patients) and progesterone (2 patients) treatment resulted in satisfactory control of bleeding. One patient with medical management required an additional balloon tamponade for symptom control. Four procedures involved the use of PVA exclusively as embolization material (500–710 μm), one involved the use of glue, and five procedures involved the combination of both as embolization materials. The glue used was NCBA with a concentration between 20 and 40% and 2–3 cc used for a single artery, and is often used with a lipiodol emulsion. All the patients underwent bilateral uterine artery embolization (UAE). Figure 1 shows an ultrasound depiction of the AVM. MRI and Angiography findings of the AVM are depicted in Figures 2 and 3, respectively. Figure 4 illustrates the UAE procedure.

Figure 1. a, b: Ultrasound diagnosis of AVM suggests convoluted vascular structure (red color) in the myometrium with color signals.

Figure 2. a, b, c: MRI depicting highly vascular structure (Blue arrow) suggestive of AVM in uterine myometrium.

Figure 3. a, b, c: Angiography suggestive of uterine AVM.

Figure 4. Uterine artery embolization procedure depicting pre-procedure, selection process and post-procedure arterial tree.

The hospital stay was 3–17 days, and nearly 19% of the patients had repeated admissions due to hematometra (n=1) and bleeding per vagina (n=2). ICU admissions were observed in two patients: one for temporal mesial sclerosis and another for multisystem dysfunction. 26% the infected patients had infections in the last 3 months, including hepatitis (n=1), endometritis (n=2), endocarditis, and pancreatitis (n=1).

Discussion

AVMs are rare entities, and two varieties of uterine AVMs have been identified. Congenital AVMs are present from birth and develop during erroneous angiogenesis at the fetal stage, leading to aberrant formation of the primitive capillary plexus with the absence of muscular and collagen tissue.^4,5 Congenital or true AVMs are diagnosed either as isolated uterine entities or as a part of extensive pelvic AVMs. Only a few hundred cases have been reported because of the rarity of the condition, and the first case was reported in 1926.^4,6 The incidence of AVMs is 0.63 following abortion or parturition.⁷ The acquired AVMs can be secondary to surgical procedures or pathologies. The most common reason is dilation and curettage (D&C) after abortion or MTP (medical termination of pregnancy).⁸ Uterine surgeries, such as myomectomy or cesarean delivery, can be iatrogenic. It can occur even after a normal delivery. Certain neoplastic conditions, such as gestational trophoblastic neoplasia and endometrial or cervical carcinoma, can even result in AVM.⁸ It has been reported following infection, hysteroscopy, intrauterine device placement, and cesarean site pregnancy in offspring exposed to diethylstilbosterone.¹ The number of acquired AVMs has increased due to both improved diagnosis and increased number of uterine surgeries in recent years.⁹ In 2015, the international society of ultrasound in obstetrics and gynecology coined the term enhanced myometrial vascularity (EMV) for RPOC-related AVMs.^2,10,11 It was almost exclusively meant in the context of recent pregnancy and hence in women of reproductive age.¹² In the literature, traumatic AVMs, arteriovenous shunts, EVMs and arteriovenous fistulas are the terms used interchangeably and are difficult to differentiate.

RPOC-related AVMs are formed between necrotic chorionic villi and venous sinuses of scar tissue. Histologically, a uterine AVM is an arteriovenous fistula between the intramural arterial branches of the uterine arteries and the myometrial venous plexus, bypassing the normal capillary system, which has an interrupted or absent elastic membrane and completely absent muscular tunica media.¹³

The spectrum of presenting symptoms varies from asymptomatic detection to catastrophic hemorrhage.¹⁴ True AVMs can have additional varicosities in the pelvic or perineal area.¹⁵ The usual symptoms are abnormal vaginal bleeding leading to anemia and, sometimes, life-threatening hemorrhagic shock. Other symptoms include pelvic pain, urinary frequency and dyspareunia.¹⁶ If not diagnosed and treated in a timely and proper manner, secondary cardiorespiratory or cerebrovascular complications may occur, which can rarely progress to multiple organ failure. The primary complaint was bleeding in 93% (14/15) of patients. Atypical symptoms such as fainting episodes, giddiness, breathlessness, and altered sensorium were present in three patients. One patient had acute kidney injury and another patient had mesial temporal sclerosis. The relationship between AVM and neuronal symptoms, such as temporal sclerosis, is not well established. However, we suggest utmost vigilance during medical therapy for patients with vaginal bleeding to prevent multisystem damage. A referral delay was observed, which needed to be curtailed by appropriate measures to achieve better outcomes.

A transvaginal scan is a primary, cost-effective, and simple screening modality, and AVMs are suspected on grayscale as enlarged anechoic vessels in the myometrium/parametrium or as myoendometrial masses with myometrial thickening.^6,17 Doppler interrogation is often diagnostic, and AVMs are depicted as enlarged, entangled, hypervascular masses with high turbulence and aliasing. It exhibits a multidirectional flow. On power Doppler, it has a high velocity and low resistance flow. It has a high peak velocity and a low RI. It has prognostic ability, as it can stratify patients at high or low risk.⁴ Thus, ultrasound and color Doppler are valuable tools for identifying AVMs.¹⁸ 3D color Doppler provides better delineation of feeding and draining vessels. We performed grayscale and color Doppler in all patients; however, power Doppler values were not consistently followed in our study.

MRI or CT is indicated when USG is unsatisfactory.⁶ It helps with pre-procedure planning. MRI/CT angiography is a better diagnostic modality for determining the lesion outlines. Uterine artery angiography (UAA), a specific application of digital subtraction angiography, is the gold standard test.^4,6 AVMs are characterized by tangled vessels containing nests, feeding arteries, draining veins, and brisk venous depletion. The utility of UAA is generally restricted for patients who would benefit from UAE because of the invasive nature of the test.¹⁷ UAA helps in differentiating AVMs from pseudoaneurysms and other vascular lesions. Overdiagnosis can occur if the disease is diagnosed using ultrasonography alone. Angiography is not always needed for diagnosis, but is essential before planning operative management or arterial embolization. Hysteroscopy may be used to diagnose and manage AVMs.¹³ We used DSA or CT/MRI angiograms as diagnostic or pretreatment tests in 93.4% of the patients.

Conclusion

AVMs are rare; however, their incidence is increasing owing to the increase in the number of uterine surgeries and improvements in diagnosis. The primary investigating modality is ultrasound with color and power Doppler imaging. Uterine artery angiography is a diagnostic method used for the detection of AVMs. Owing to these rare conditions, no treatment guidelines are available. Each case must be individualized. Conservative treatment is an option in mild cases. It also helps retain fertility. Surgical management is the treatment of choice in severe cases without reproductive desire.

Ethical approval

The study was approved by Kasturba Medical College and Kasturba Hospital, Institutional Ethical Committee, IEC 1: 166/2025. Date: 23 April 2025.

Ethical standards and research involving human participants: The study involving human participants followed the ethical standards of the institute’s ethical and research committee and the 1964 Helsinki Declaration and its later amendments.

Consent

Written informed consent was obtained from patients.